TP53 and acute myeloid leukemia: HDM201 in combination with Fms-like tyrosine kinase 3 (FLT3) inhibitors specifically induces apoptosis and death of FLT3-itd positive TP53 wild-type AML cells [96], suggesting that HDM201 has the potential to be combined with other targeted drugs.